Our Company

Targeting Unmet Disease Through Development of Best-in-Class Therapies

We are a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal, or GI, diseases. Our most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. We have leveraged our chemistry and biology platform to internally discover a proprietary portfolio of non-bile acid FXR agonists. We purposefully design our product candidates, to be optimized, next-generation FXR agonists that we are initially developing as a differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, we plan to evaluate our FXR agonists as a potential first-in-class treatment for inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease and irritable bowel syndrome with diarrhea (IBS‑D). Beyond our FXR program, we are building a pipeline of novel drug candidates against other drug targets by taking advantage of our drug discovery and development capabilities.

NASH is projected to be the leading cause of liver transplant by the end of 2020.

Since our founding in 2014, we invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities give us insight into disease targets and mechanisms and enable us to quickly and purposefully design drugs with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed our proprietary FXR product candidates and have identified a potential role for them in the treatment of NASH, IBS‑D and IBD. We have purposefully designed compounds to be non-bile acid, sustained engagement FXR agonists with high potency that could be dosed orally once-daily.